Page 4 - Fastpharming Contract Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

[December 28, 2020]
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020.
“We are thrilled to have Dr. Brenner join our team,” said Tom Isett, Chairman & CEO of iBio. “Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation, as well as establishing productive collaborations.” ....

United States , Martinb Brenner , Tom Isett , Stephen Kilmer , Eli Lilly , Fastpharming Contract Development , Recursion Pharmaceuticals Inc , Veterinary School Of Hannover , Head Of The Insulin Resistance Group , Pfenex Inc , While The Company , Company Annual Report On Form , Pfizer Inc , Glycaneering Development Service , Good Research Practice , Company Lilly , Research Fellow At Pfizer , Pfenex Expression Technology , Ligand Pharmaceuticals Incorporated , Bio Inc , Manufacturing Services , Ludwig Maximilian University Of Munich , Merck Research Laboratories Merk , Bio Appoints , Chief Scientific , Chief Scientific Officer ,